Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Tumor Biology

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13277-015-3265-xPMID 26462835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Thymus serpyllum Extract on Cell Proliferation, Apoptosis and Epigenetic Events in Human Breast Cancer Cells

  2012cited by this paper
• Zoledronic acid for adjuvant use in patients with breast cancer

  2011cited by this paper
• Direct antitumour activity of zoledronic acid: preclinical and clinical data

  2011cited by this paper
• Targeting the PI3K signaling pathway in cancer.

  2010cited by this paper
• Laminin regulates PI3K basal localization and activation to sustain STAT5 activation

  2010cited by this paper
• Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation

  2010cited by this paper
• Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells.

  2010cited by this paper
• The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

  2009cited by this paper
• Multiple signal transduction pathways in okadaic acid induced apoptosis in HeLa cells.

  2009cited by this paper
• Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl‐2 protein level in hormone‐refractory prostate cancer cells

  2009cited by this paper
• Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.

  2007cited by this paper
• The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.

  2007cited by this paper
• Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro

  2007cited by this paper
• Akt and Erk signal transduction pathways are early markers of differentiation in dominant and subordinate ovarian follicles in cattle.

  2007cited by this paper
• Structural Basis for the Exceptional in vivo Efficacy of Bisphosphonate Drugs

  2006cited by this paper
• Molecular Mechanisms of Action of Bisphosphonates: Current Status

  2006cited by this paper
• Activation of PI3K/Akt signaling and hormone resistance in breast cancer

  2006cited by this paper
• Anti-tumour activity of zoledronic acid.

  2005cited by this paper
• Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity.

  2005cited by this paper
• Bisphosphonates: preclinical review.

  2004cited by this paper
• The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate

  2004cited by this paper
• Protein phosphatase 1--targeted in many directions.

  2002cited by this paper
• Reduced expression of PTEN correlates with breast cancer progression.

  2002cited by this paper
• Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

  2002cited by this paper
• Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits

  2002cited by this paper
• Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta.

  2002cited by this paper
• The role of bisphosphonates in breast cancer: The present and future role of bisphosphonates in the management of patients with breast cancer

  2001cited by this paper
• Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling.

  2001cited by this paper
• Effects of serine/threonine protein phosphatases on ion channels in excitable membranes.

  2000cited by this paper
• Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

  1999cited by this paper
• Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.

  1999cited by this paper
• Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates.

  1999cited by this paper
• Cellular survival: a play in three Akts.

  1999cited by this paper
• Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras

  1998cited by this paper
• Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress.

  1998cited by this paper
• Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

  1997cited by this paper
• Bcl-2 Phosphorylation Required for Anti-apoptosis Function*

  1997cited by this paper
• Specific Recognition of an rU2-N15-rU Motif by VP55, the Vaccinia Virus Poly(A) Polymerase Catalytic Subunit*

  1997cited by this paper
• Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate

  1997cited by this paper
• Differential Inhibition and Posttranslational Modification of Protein Phosphatase 1 and 2A in MCF7 Cells Treated with Calyculin-A, Okadaic Acid, and Tautomycin*

  1997cited by this paper
• Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.

  1997cited by this paper
• Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors.

  1996cited by this paper
• Tumor promotion by inhibitors of protein phosphatases 1 and 2A: the okadaic acid class of compounds.

  1993cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Targeting of Mevalonate-Isoprenoid Pathway in Acute Myeloid Leukemia Cells by Bisphosphonate Drugs

  2022cites this paper
• Periplocymarin Induced Colorectal Cancer Cells Apoptosis Via Impairing PI3K/AKT Pathway

  2021cites this paper
• AZD3463, an IGF-1R inhibitor, suppresses breast cancer metastasis to bone via modulation of the PI3K-Akt pathway

  2020cites this paper
• CD44 induced enhancement of phosphatase activity and calcium influx: Modifications of EGR-1 expression and cell proliferation

  2016cites this paper